About the Summit

Thank You to our Speakers, Delegates and Sponsors who joined us in Boston for the 7th DDR Inhibitors Summit!

For its 7th year, this industry-focused meeting returned as the community hotspot for DDR inhibitors. To effectively address your main challenges, the pre-conference biomarker focus day set out to help you develop dynamic range biomarkers, improve pharmacodynamic studies, and optimize patient stratification for DDR inhibitor combination therapies.

The main conference days were split into two unmissable tracks: discovery, and preclinical and clinical update. The discovery track unravelled the complexity of DDR pathways and uncovered novel targets including damage sensors and repair proteins. The preclinical and clinical track delved into monotherapies and combinations, both of which have advanced through clinical studies to create novel therapies treating multiple cancer types including castration-resistant prostate cancers, breast, ovarian, and glioblastoma.

The Community United To:

5 Key Takeaways 1

Innovate assay development to unravel complex interconnected DDR pathways and identify and validate novel targets for your pipeline

5 Key Takeaways 2

Uncover the new targets which are achieving the most clinical success, to access cutting-edge DDR inhibitor therapies that can provide new treatment options and improve survival rates

5 Key Takeaways 3

Resolve why monotherapies are experiencing less clinical success than previously expected. Are combinations the answer? Will a novel target be the next PARP inhibitor? Can these novel DDR inhibitors conclusively treat cancer or become safe maintenance therapies?

5 Key Takeaways 4

Explore how to implement computational methods to create patient-centric novel therapeutic candidates with increased specificity and decreased toxicity

5 Key Takeaways 5

Solidify your knowledge in DDR inhibitor development and learn how to seamlessly apply your insight to other therapeutic areas such as fibrosis

Who Was There?

A diverse audience of C-level executives, directors, clinicians, and scientists covering discovery and translation,
all dedicated to DDR inhibitor development.

What Your Peers Have to Say:

Great opportunity to network in a small environment with key experts.Executive Director & Head of Haematology Global Regulatory Affairs, AstraZeneca

EMD Serano

There was a good amount of time for questions and discussion after the talks or in the roundtable panel discussions. These were good quality questions concerning translational, biomarkers and safety aspects of DDR therapeutics.Director  Oncology Translational & Biomarker Research, EMD Serono